Drug intelligence / Profile preview

LY3875383

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Subcutaneous

Overview

LY3875383 is an investigational drug developed by Eli Lilly for the treatment of hypertriglyceridemia. It is currently in phase 1 clinical trials. The drug is administered as a single subcutaneous injection and has been studied in both healthy participants and those with elevated triglyceride levels to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics. LY3875383 acts as an apolipoprotein C-III (APOC3) inhibitor to reduce triglyceride levels in the blood. It belongs to the class of antihyperlipidaemics.

Targets

APOC3 (Apolipoprotein C-III)

Beyond the preview

Go deeper on LY3875383.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY3875383.

Explore the full profile